Navigation Links
PSA 'Nanotest' May Spot Prostate Cancer's Return After Surgery
Date:10/19/2009

Screen could boost accuracy but is still years away from approval, experts say

MONDAY, Oct. 19 (HealthDay News) -- A new test that could revolutionize the treatment of men following prostate cancer surgery has worked well in a small, early trial, researchers report.

Using nanotechnology, the researchers were able to detect prostate-specific antigen (PSA), the cancer-associated protein, at levels far below what is now possible with older technology, explained Chad A. Mirkin, lead author of a report published online Oct. 19 in Proceedings of the National Academy of Sciences.

"This could knock years off our current ability to detect a recurrence of cancer," said Mirkin, a professor of chemistry at Northwestern University in Chicago.

But it will be "a number of years" before the assay, or test, undergoes the larger-scale testing and vetting needed for approval of its use in medical practice, said Dr. C. Shad Thaxton, assistant professor of urology at Northwestern's Feinberg School of Medicine, one of Mirkin's collaborators in development of the test.

The ultra-sensitive PSA test uses gold particles that are just 30 nanometers in diameter and have antibodies to PSA as well as strands of DNA, the basic genetic molecule, attached to them. The combination allows detection of PSA at levels 300 times lower than is now possible, Mirkin said.

PSA testing is controversial when it is used to screen for prostate cancer, he acknowledged. "But no one is arguing that a rising PSA level is not a marker of recurrence," Mirkin said.

He envisions use of the PSA nanotest routinely in men after prostate surgery. "It can stratify the population post-operatively," Mirkin said. "About 42 percent of the time there will be no recurrence, and this test will allow us to determine that years earlier than we can with conventional tools."

If rapidly rising PSA levels are detected, "there is no definitive therapy, but we can offer experimental chemotherapy or radiotherapy and can validate whether those therapies are working," he said.

That knowledge could be invaluable, the researchers believe. "If the treatment is not working, we can try a different approach," Thaxton said.

The journal report describes use of the nanotest for 18 men who had prostate cancer surgery. A larger study, with 260 participants, is also under way at Northwestern. "We hope to have data by the end of the year," Mirkin said.

Even larger studies that are necessary to validate the assay could start "within a year or two," Thaxton said.

Both Mirkin and Thaxton are stockholders in Nanosphere, Inc., the company that has licensed the nanotechnology from Northwestern and is applying it to a wide variety of medical tests.

"They have six FDA approvals already," Mirkin said of the company's medical nanotechnology tests. Approval by the U.S. Food and Drug Administration is required for a test to be used in medical practice in the United States.

For now, caution is needed until widespread studies are done, said Dr. Durado Brooks, director of prostate and colorectal cancers at the American Cancer Society.

"We're talking about only 18 patients, but more importantly, we still don't know if this is clinically significant," Brooks said. "If we find a recurrence earlier, does it make a difference if we treat it earlier? We don't know if it will make a difference long-term."

While he called the work "exciting," Brooks said "it is way too early in the game to tell whether it will have clinical significance."

More information

For more on PSA testing, see the U.S. National Institutes of Health.



SOURCES: Chad A. Mirkin, Ph.D, professor, chemistry, Northwestern University, Chicago; C. Shad Thaxton, M.D., assistant professor, urology, Feinberg School of Medicine, Chicago; Durado Brooks, M.D., director, prostate and colorectal cancers, American Cancer Society, Atlanta; Oct. 19, 2009, Proceedings of the National Academy of Sciences


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Detecting the undetectable in prostate cancer screening
2. Impotence, Incontinence Risk Casts Doubt on High-Tech Prostate Surgery
3. SRI International Awarded a Department of Defense Laboratory-Clinical Transition Grant to Advance SRIs Novel Anticancer Agents for Prostate Cancer Treatment
4. Minimally invasive radical prostatectomy shows advantages, but also certain complications
5. PMH clinicians map group at high risk for aggressive, hidden prostate cancer
6. Prostate cancer gives a new outlook on life
7. UNC expert: Better decision support tools needed for prostate cancer screening choice
8. Mayo researchers find few side effects from radiation treatment given after prostate cancer surgery
9. Swiss study finds income affects prostate cancer patients survival
10. Exercise May Prevent Prostate Cancer: Study
11. Study reveals 2/3 of prostate cancer patients do not need treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
Breaking Medicine Technology: